- Home
- SWTX
as 06-30-2025 12:33pm EST
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | STAMFORD |
| Market Cap: | 3.5B | IPO Year: | 2019 |
| Target Price: | $56.86 | AVG Volume (30 days): | 4.5M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $28.21 - $62.00 | Next Earning Date: | 08-06-2025 |
| Revenue: | $219,670,000 | Revenue Growth: | 730.42% |
| Revenue Growth (this year): | 74.36% | Revenue Growth (next year): | 75.63% |
Latest SpringWorks Therapeutics Inc. News
SWTX Breaking Stock News: Dive into SWTX Ticker-Specific Updates for Smart Investing
Insider Monkey
7 days ago
SpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, Nirogacestat
GlobeNewswire
11 days ago
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Simply Wall St.
a month ago
High Growth Tech Stocks in the US to Watch This May 2025
GlobeNewswire
a month ago
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
TipRanks
2 months ago
Biotech Alert: Searches spiking for these stocks today
Yahoo Finance Video
2 months ago
Temu, Tesla prices, Merck KGaA deal: Trending Tickers
The Wall Street Journal
2 months ago
Germany’s Merck Set to Buy SpringWorks in $3.9 Billion Deal
GlobeNewswire
2 months ago
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
Compare SWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SWTX SpringWorks Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.